Interaction of phenothiazine derivatives with human ceruloplasmin.
D014150:Antipsychotic Agents / Q000378:metabolism*; D001205:Ascorbic Acid / Q000494:pharmacology; D001798:Blood Proteins / Q000378:metabolism; D002570:Ceruloplasmin / Q000378:metabolism*; D002746:Chlorpromazine / Q000378:metabolism; D004295:Dihydroxyphenylalanine / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology; D005978:Glutathione / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007501:Iron / Q000494:pharmacology; D007700:Kinetics; D009682:Magnetic Resonance Spectroscopy; D008728:Methotrimeprazine / Q000378:metabolism; D009243:NAD / Q000494:pharmacology; D009249:NADP / Q000494:pharmacology; D010084:Oxidation-Reduction; D011395:Promazine / Q000378:metabolism; D011485:Protein Binding; D013053:Spectrophotometry; D013268:Stimulation, Chemical; D013431:Sulfates / Q000494:pharmacology; D014273:Triflupromazine / Q000378:metabolism
D014150:Antipsychotic Agents; D001798:Blood Proteins; D013431:Sulfates; D009243:NAD; D009249:NADP; D004295:Dihydroxyphenylalanine; D008728:Methotrimeprazine; D007501:Iron; D002570:Ceruloplasmin; D005978:Glutathione; D011395:Promazine; D001205:Ascorbic Acid; D014273:Triflupromazine; D002746:Chlorpromazine; D004298:Dopamine